Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 54.2% in March

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 13,325 shares, an increase of 54.2% from the March 15th total of 8,642 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 18,013 shares, the days-to-cover ratio is currently 0.7 days.

Indaptus Therapeutics Trading Up 10.7%

Indaptus Therapeutics stock traded up $0.22 during midday trading on Tuesday, hitting $2.28. The stock had a trading volume of 189,512 shares, compared to its average volume of 66,469. The stock has a market cap of $5.11 million, a P/E ratio of -0.09 and a beta of 0.97. The business has a fifty day moving average price of $1.83 and a 200 day moving average price of $2.47. Indaptus Therapeutics has a 12 month low of $1.51 and a 12 month high of $19.91.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Tuesday, March 17th. The company reported ($3.10) EPS for the quarter, beating the consensus estimate of ($4.36) by $1.26. On average, equities analysts anticipate that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.